Clinical utility of mesenchymal stem/stromal cells in regenerative medicine and cellular therapy

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Mesenchymal stem/stromal cells (MSCs) have been carefully examined to have tremendous potential in regenerative medicine. With their immunomodulatory and regenerative properties, MSCs have numerous applications within the clinical sector. MSCs have the properties of multilineage differentiation, paracrine signaling, and can be isolated from various tissues, which makes them a key candidate for applications in numerous organ systems. To accentuate the importance of MSC therapy for a range of clinical indications, this review highlights MSC-specific studies on the musculoskeletal, nervous, cardiovascular, and immune systems where most trials are reported. Furthermore, an updated list of the different types of MSCs used in clinical trials, as well as the key characteristics of each type of MSCs are included. Many of the studies mentioned revolve around the properties of MSC, such as exosome usage and MSC co-cultures with other cell types. It is worth noting that MSC clinical usage is not limited to these four systems, and MSCs continue to be tested to repair, regenerate, or modulate other diseased or injured organ systems. This review provides an updated compilation of MSCs in clinical trials that paves the way for improvement in the field of MSC therapy.

Related collections

Most cited references 128

Record: found
Abstract: found
Article: not found

Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement.

M Dominici, K Le Blanc, I. Mueller … (2006)

The considerable therapeutic potential of human multipotent mesenchymal stromal cells (MSC) has generated markedly increasing interest in a wide variety of biomedical disciplines. However, investigators report studies of MSC using different methods of isolation and expansion, and different approaches to characterizing the cells. Thus it is increasingly difficult to compare and contrast study outcomes, which hinders progress in the field. To begin to address this issue, the Mesenchymal and Tissue Stem Cell Committee of the International Society for Cellular Therapy proposes minimal criteria to define human MSC. First, MSC must be plastic-adherent when maintained in standard culture conditions. Second, MSC must express CD105, CD73 and CD90, and lack expression of CD45, CD34, CD14 or CD11b, CD79alpha or CD19 and HLA-DR surface molecules. Third, MSC must differentiate to osteoblasts, adipocytes and chondroblasts in vitro. While these criteria will probably require modification as new knowledge unfolds, we believe this minimal set of standard criteria will foster a more uniform characterization of MSC and facilitate the exchange of data among investigators.

0 comments Cited 2480 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: found

Is Open Access

From Monocytes to M1/M2 Macrophages: Phenotypical vs. Functional Differentiation

Paola Italiani, Diana Boraschi (2014)

Studies on monocyte and macrophage biology and differentiation have revealed the pleiotropic activities of these cells. Macrophages are tissue sentinels that maintain tissue integrity by eliminating/repairing damaged cells and matrices. In this M2-like mode, they can also promote tumor growth. Conversely, M1-like macrophages are key effector cells for the elimination of pathogens, virally infected, and cancer cells. Macrophage differentiation from monocytes occurs in the tissue in concomitance with the acquisition of a functional phenotype that depends on microenvironmental signals, thereby accounting for the many and apparently opposed macrophage functions. Many questions arise. When monocytes differentiate into macrophages in a tissue (concomitantly adopting a specific functional program, M1 or M2), do they all die during the inflammatory reaction, or do some of them survive? Do those that survive become quiescent tissue macrophages, able to react as naïve cells to a new challenge? Or, do monocyte-derived tissue macrophages conserve a “memory” of their past inflammatory activation? This review will address some of these important questions under the general framework of the role of monocytes and macrophages in the initiation, development, resolution, and chronicization of inflammation.

0 comments Cited 456 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Osteoarthritis.

Mary Goldring, Steven R Goldring (2007)

Osteoarthritis (OA) is characterized by degeneration of articular cartilage, limited intraarticular inflammation with synovitis, and changes in peri-articular and subchondral bone. Multiple factors are involved in the pathogenesis of OA, including mechanical influences, the effects of aging on cartilage matrix composition and structure, and genetic factors. Since the initial stages of OA involve increased cell proliferation and synthesis of matrix proteins, proteinases, growth factors, cytokines, and other inflammatory mediators by chondrocytes, research has focused on the chondrocyte as the cellular mediator of OA pathogenesis. The other cells and tissues of the joint, including the synovium and subchondral bone, also contribute to pathogenesis. The adult articular chondrocyte, which normally maintains the cartilage with a low turnover of matrix constituents, has limited capacity to regenerate the original cartilage matrix architecture. It may attempt to recapitulate phenotypes of early stages of cartilage development, but the precise zonal variations of the original cartilage cannot be replicated. Current pharmacological interventions that address chronic pain are insufficient, and no proven structure-modifying therapy is available. Cartilage tissue engineering with or without gene therapy is the subject of intense investigation. There are multiple animal models of OA, but there is no single model that faithfully replicates the human disease. This review will focus on questions currently under study that may lead to better understanding of mechanisms of OA pathogenesis and elucidation of effective strategies for therapy, with emphasis on mechanisms that affect the function of chondrocytes and interactions with surrounding tissues. 2007 Wiley-Liss, Inc.

0 comments Cited 338 times – based on 0 reviews      Review now

Bookmark

All references

Author and article information

Contributors

Rebekah M. Samsonraj: rmsamson@uark.edu

Journal

Journal ID (nlm-ta): J Biol Eng

Journal ID (iso-abbrev): J Biol Eng

Title: Journal of Biological Engineering

Publisher: BioMed Central (London )

ISSN (Electronic): 1754-1611

Publication date (Electronic): 11 July 2023

Publication date PMC-release: 11 July 2023

Publication date Collection: 2023

Volume: 17

Electronic Location Identifier: 44

Affiliations

[1 ]GRID grid.411017.2, ISNI 0000 0001 2151 0999, Department of Biomedical Engineering, , University of Arkansas, ; 790 W Dickson St, Fayetteville, AR USA

[2 ]GRID grid.241054.6, ISNI 0000 0004 4687 1637, Department of Orthopedic Surgery, , University of Arkansas for Medical Sciences, ; Little Rock, AR USA

[3 ]GRID grid.470142.4, ISNI 0000 0004 0443 9766, Nyberg Human Cellular Therapy Laboratory, , Mayo Clinic, ; Phoenix, AZ USA

[4 ]GRID grid.411017.2, ISNI 0000 0001 2151 0999, Interdisciplinary Graduate Program in Cell and Molecular Biology, , University of Arkansas, ; Fayetteville, AR USA

Article

Publisher ID: 361

DOI: 10.1186/s13036-023-00361-9

PMC ID: 10334654

PubMed ID: 37434264

SO-VID: c4b1b12d-3aa7-419a-9785-d43f682d9b63

License:

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

History

Date received : 17 December 2022

Date accepted : 19 June 2023

Custom metadata

ScienceOpen disciplines: Biotechnology

Keywords: mesenchymal stem/stromal cells,mscs,clinical trials,musculoskeletal,cardiovascular,nervous system,immune system disorders,regenerative medicine

Data availability:

ScienceOpen disciplines: Biotechnology

Keywords: mesenchymal stem/stromal cells, mscs, clinical trials, musculoskeletal, cardiovascular, nervous system, immune system disorders, regenerative medicine

Clinical utility of mesenchymal stem/stromal cells in regenerative medicine and cellular therapy

Read this article at

Abstract

Related collections

Genome Engineering using CRISPR

Most cited references 128

Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement.

From Monocytes to M1/M2 Macrophages: Phenotypical vs. Functional Differentiation

Osteoarthritis.

Author and article information

Contributors

Journal

Affiliations

Article

History

Categories

Custom metadata

Comments

Comment on this article

Similar content 322

Cited by 4

Most referenced authors 2,119